Search Result
Results for "
item/HY-B0356
" in MedChemExpress (MCE) Product Catalog:
3
Biochemical Assay Reagents
6
Isotope-Labeled Compounds
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-B0356
-
-
-
- HY-B0356B
-
|
Bay-09867 HYdrochloride monoHYdrate
|
Topoisomerase
Apoptosis
Antibiotic
Bacterial
Mitochondrial Metabolism
Reactive Oxygen Species (ROS)
|
Infection
Cancer
|
|
Ciprofloxacin (Bay-09867) hydrochloride monohydrate is a potent, orally active topoisomerase IV inhibitor. Ciprofloxacin hydrochloride monohydrate induces mitochondrial DNA and nuclear DNA damage and lead to mitochondrial dysfunction, ROS production. Ciprofloxacin hydrochloride monohydrate has anti-proliferative activity and induces apoptosis. Ciprofloxacin hydrochloride monohydrate is a fluoroquinolone antibiotic, exhibiting potent antibacterial activity .
|
-
-
- HY-B0356A
-
|
Bay-09867 monoHYdrochloride
|
Topoisomerase
Apoptosis
Antibiotic
Bacterial
Mitochondrial Metabolism
Reactive Oxygen Species (ROS)
|
Infection
Cancer
|
|
Ciprofloxacin (Bay-09867) monohydrochloride is a potent, orally active topoisomerase IV inhibitor. Ciprofloxacin monohydrochloride induces mitochondrial DNA and nuclear DNA damage and lead to mitochondrial dysfunction, ROS production. Ciprofloxacin monohydrochloride has anti-proliferative activity and induces apoptosis. Ciprofloxacin monohydrochloride is a fluoroquinolone antibiotic, exhibiting potent antibacterial activity .
|
-
-
- HY-B0356S1
-
|
Bay-09867-d8
|
Bacterial
Antibiotic
|
Infection
|
|
Ciprofloxacin-d8 is the deuterium labeled Ciprofloxacin. Ciprofloxacin (Bay-09867) is a fluoroquinolone antibiotic, exhibiting potent antibacterial activity.
|
-
-
- HY-Y1718
-
|
N-Tridecanoic acid
|
Endogenous Metabolite
Bacterial
|
Infection
|
|
Tridecanoic acid (N-Tridecanoic acid) is a medium-chain saturated fatty acid and inhibitor with no antibacterial activity against enterohemorrhagic E. coli (EHEC). When used in combination with Ciprofloxacin (HY-B0356) or Ampicillin (HY-B0522), Tridecanoic acid suppresses persister formation in exponentially growing E. coli and EHEC, but exerts no inhibitory effect on persister formation induced by Kanamycin (HY-16566) or in stationary-phase cells. Tridecanoic acid inhibits biofilm formation in EHEC. It can be used in the research of bacterial infections .
|
-
-
- HY-B0356S
-
|
Bay-09867-d8 HYdrochloride
|
Bacterial
Antibiotic
|
Infection
|
|
Ciprofloxacin-d8 (hydrochloride) is the deuterium labeled Ciprofloxacin. Ciprofloxacin (Bay-09867) hydrochloride is a fluoroquinolone antibiotic, exhibiting potent antibacterial activity.
|
-
-
- HY-B0356R
-
|
Bay-09867 (Standard)
|
Reference Standards
Topoisomerase
Apoptosis
Antibiotic
Bacterial
Mitochondrial Metabolism
Reactive Oxygen Species (ROS)
|
Infection
Cancer
|
|
Ciprofloxacin (Standard) is the analytical standard of Ciprofloxacin. This product is intended for research and analytical applications. Ciprofloxacin (Bay-09867) is a potent, orally active topoisomerase IV inhibitor. Ciprofloxacin induces mitochondrial DNA and nuclear DNA damage and lead to mitochondrial dysfunction, ROS production. Ciprofloxacin has anti-proliferative activity and induces apoptosis. Ciprofloxacin is a fluoroquinolone antibiotic, exhibiting potent antibacterial activity .
|
-
-
- HY-B0356BR
-
|
Bay-09867 HYdrochloride monoHYdrate (Standard)
|
Reference Standards
Topoisomerase
Apoptosis
Antibiotic
Bacterial
Mitochondrial Metabolism
Reactive Oxygen Species (ROS)
|
Infection
Cancer
|
|
Ciprofloxacin (hydrochloride monohydrate) (Standard) is the analytical standard of Ciprofloxacin (hydrochloride monohydrate). This product is intended for research and analytical applications. Ciprofloxacin (Bay-09867) hydrochloride monohydrate is a potent, orally active topoisomerase IV inhibitor. Ciprofloxacin hydrochloride monohydrate induces mitochondrial DNA and nuclear DNA damage and lead to mitochondrial dysfunction, ROS production. Ciprofloxacin hydrochloride monohydrate has anti-proliferative activity and induces apoptosis. Ciprofloxacin hydrochloride monohydrate is a fluoroquinolone antibiotic, exhibiting potent antibacterial activity .
|
-
-
- HY-W105318
-
|
PBP
|
TGF-beta/Smad
Apoptosis
|
Cancer
|
|
Pentabromophenol (PBP) is a brominated flame retardant (BFR) widely used in various consumer products to reduce the flammability of materials used in different utility items. Pentabromophenol can accelerate the degradation of transforming growth factor-β (TGF-β) receptors by promoting clathrin-mediated endocytosis, thereby inhibiting the TGF-β signaling pathway. Additionally, Pentabromophenol can also induce apoptosis in peripheral blood mononuclear cells (PBMCs) .
|
-
-
- HY-B0356AS1
-
-
-
- HY-177716
-
|
|
Beta-lactamase
Bacterial
|
Infection
|
|
Ciprofloxacin prodrug-1 (Compound 35) is an activated prodrug of β-lactase. Ciprofloxacin prodrug-1 exhibits good antibacterial activity against bacteria containing β-lactase (MIC = 63 nM). After being hydrolyzed by β-lactase, Ciprofloxacin prodrug-1 can release Ciprofloxacin (HY-B0356), thereby inhibiting the activity of DNA gyrase. Ciprofloxacin prodrug-1 can be used to study infections caused by enzyme-producing drug-resistant bacteria (such as uropathogenic Escherichia coli) .
|
-
-
- HY-122139
-
|
|
Bacterial
|
Infection
|
|
Desethylene Ciprofloxacin hydrochloride is a major metabolite of Ciprofloxacin (HY-B0356). Ciprofloxacin is an orally active topoisomerase IV inhibitor. Desethylene Ciprofloxacin hydrochloride has antibacterial activity .
|
-
-
- HY-145525
-
|
CAR 18:2; C18:2 Carnitine; L-Carnitine linoleoyl ester
|
Endogenous Metabolite
|
Others
|
|
Linoleoyl-L-carnitine is a naturally occurring long-chain acylcarnitine. Hepatic levels of linoleoyl-L-carnitine are increased following high-dose (200 mg/kg) administration of Isoniazid (Item No. 20378) in mice.
|
-
-
- HY-137555
-
|
11-deHYdro-2,3-dinor TXB2
|
Endogenous Metabolite
|
Metabolic Disease
|
|
11-dehydro-2,3-dinor Thromboxane B2 (11-dehydro-2,3-dinor TXB2) is a metabolite of the TXA2 inactive metabolite TXB2 (Item No. 19030). It is formed from TXB2 by cytosolic aldehyde dehydrogenase (ALDH) and β-oxidation. Levels of 11-dehydro-2,3-dinor TXB2 are increased 5.2-fold in a surgery-induced rat model of tendon overuse.
|
-
-
- HY-W114419
-
|
|
Estrogen Receptor/ERR
mTOR
|
Cardiovascular Disease
Metabolic Disease
|
|
Bisphenol C is an estrogen receptor-α (ERα) agonist and an ERβ antagonist, with IC50 values of 2.65 nM for ERα and 1.94 nM for ERβ. Bisphenol C is a material of manufacturing polyester polymers like polycarbonate, is widely used in daily items like water bottles, food packaging, textile and so on .
|
-
-
- HY-B0356AS
-
|
Bay-09867-d8 HYdrochloride HYdrate
|
Isotope-Labeled Compounds
Bacterial
Antibiotic
|
Infection
|
|
Ciprofloxacin-d8 (hydrochloride hydrate) is the deuterium labeled Ciprofloxacin hydrochloride monohydrate. Ciprofloxacin hydrochloride monohydrate is a fluoroquinolone antibiotic, exhibiting potent antibacterial activity.
|
-
-
- HY-B0356AR
-
|
Bay-09867 monoHYdrochloride (Standard)
|
Reference Standards
Topoisomerase
Apoptosis
Antibiotic
Bacterial
Mitochondrial Metabolism
Reactive Oxygen Species (ROS)
|
Infection
Cancer
|
|
Ciprofloxacin (monohydrochloride) (Standard) is the analytical standard of Ciprofloxacin (monohydrochloride). This product is intended for research and analytical applications. Ciprofloxacin (Bay-09867) monohydrochloride is a potent, orally active topoisomerase IV inhibitor. Ciprofloxacin monohydrochloride induces mitochondrial DNA and nuclear DNA damage and lead to mitochondrial dysfunction, ROS production. Ciprofloxacin monohydrochloride has anti-proliferative activity and induces apoptosis. Ciprofloxacin monohydrochloride is a fluoroquinolone antibiotic, exhibiting potent antibacterial activity [4].
|
-
-
- HY-B0356BS
-
|
Bay-09867-d8 HYdrochloride monoHYdrate
|
Isotope-Labeled Compounds
Bacterial
Antibiotic
|
Infection
|
|
Ciprofloxacin-d8 (hydrochloride monohydrate) is the deuterium labeled Ciprofloxacin (hydrochloride monohydrate). Ciprofloxacin hydrochloride is a fluoroquinolone antibiotic, exhibiting potent antibacterial activity.
|
-
-
- HY-B0356S2
-
-
-
- HY-W753945
-
-
-
- HY-N8606
-
-
-
- HY-120011
-
|
|
Bacterial
|
Others
|
|
Ro 24-6392 is an ester-linked co-drug combining Ciprofloxacin (HY-B0356) and Desacetylcefotaxime (HY-126129) with inhibitory activity against a variety of aerobic bacteria in vitro.
|
-
-
- HY-122139R
-
|
|
Bacterial
Reference Standards
|
Infection
|
|
Desethylene Ciprofloxacin (hydrochloride) (Standard) is the analytical standard of Desethylene Ciprofloxacin (hydrochloride). This product is intended for research and analytical applications. Desethylene Ciprofloxacin hydrochloride is a major metabolite of Ciprofloxacin (HY-B0356). Ciprofloxacin is an orally active topoisomerase IV inhibitor. Desethylene Ciprofloxacin hydrochloride has antibacterial activity .
|
-
-
- HY-151944
-
|
|
Bacterial
Antibiotic
|
Infection
|
|
Antibacterial agent 128 is a siderophore analog-Ciprofloxacin (HY-B0356) conjugate with a cleavable linker. Antibacterial agent 128 shows antibiotic activities against P. aeruginosa (MIC values of 0.25-64 μg/mL) and B. pseudomallei (MIC values of 1-32 μg/mL) .
|
-
-
- HY-116661
-
|
CBGV
|
Cannabinoid Receptor
|
Metabolic Disease
|
|
Cannabigerovarin (CRM) (Item No. 29117) is a certified reference material categorized as a phytocannabinoid.1 This product is intended for research and forensic applications.
|
-
-
- HY-NP0248
-
|
|
Biochemical Assay Reagents
|
Inflammation/Immunology
|
|
Ciprofloxacin-BSA is a conjugate of Ciprofloxacin (HY-B0356) and BSA. By conjugating the antigen with protein adjuvants, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt the primary epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells .
|
-
-
- HY-149333
-
|
|
Bacterial
|
Infection
|
|
BO-1 is a benzoate ester with antibacterial activity. BO-1 inhibits multidrug-resistant Staphylococcus aureus, and acts function synergistically with antibiotic, such as Ciprofloxacin (HY-B0356). BO-1 can reverse the resistance of antibiotic-resistant S. aureus strains, and decreases the level of inflammatory factors IL-6 and C-reactive protein in vivo in mice .
|
-
-
- HY-149881
-
|
|
Bacterial
|
Infection
|
|
Quorum sensing-IN-2 (compound 23e) is a quorum sensing inhibitor, which can reduce the pathogenicity of bacteria without affecting bacterial growth. Quorum sensing-IN-2 inhibits bacterial infections with little hemolytic activity. Quorum sensing-IN-2 shows synergistic effect with Ciprofloxacin (HY-B0356) in the bacteremia model infected with P. aeruginosa PAO1 .
|
-
-
- HY-168631
-
|
|
Bacterial
|
Infection
|
|
Antibacterial agent 254 (Compound 2) is a dispersion sensor (DspS) activator that disperses Pseudomonas aeruginosa biofilms. Antibacterial agent 254 can dislodge 7-day P. aeruginosa biofilms at 50 μM. Antibacterial agent 254 also enhances the effects of Ciprofloxacin (HY-B0356) against P. aeruginosa and increases the expression of matrix-degrading enzyme genes pelA, pslG and eddA .
|
-
-
- HY-123508
-
|
|
Drug Metabolite
Bacterial
|
Infection
|
|
PD 131628 is an antimicrobial agent and active PD 131112 metabolite. PD 131628 is two- to four-fold more active than Ciprofloxacin (HY-B0356), inhibiting all strains of Staphylococcus aureus and Streptococcus pneumoniae. PD 131628 is very active against Neisseria spp., Haemophilus influenzae and Moraxella catarrhalis, with MIC90s ranging from 0.004 to 0.008 mg/L .
|
-
-
- HY-155479
-
|
|
Bacterial
|
Infection
|
|
PqsR-IN-3 (compound 16e) is a selective inhibitor of the pqs system (IC50=3.7 μM) and its associated virulence factor pyocyanin (IC50=2.7 μM). PqsR-IN-3 inhibits bacterial biofilm synthesis and is significantly cytotoxic against Pseudomonas aeruginosa. PqsR-IN-3 has synergistic effects with several antibiotics, such as Ciprofloxacin (HY-B0356) and Tobramycin (HY-B0441) .
|
-
-
- HY-173270
-
|
|
Bacterial
|
Infection
|
|
Antibacterial synergist 3 is a dual-acting inhibitor of biofilm (IC50 of PAO1: 0.40 μM and IC50 of PA14: 1.45 μM). Antibacterial synergist 3 reduces virulence production by inhibiting the quorum sensing (QS) system and induces iron deficiency in P. aeruginosa PAO1. Antibacterial synergist 3 enhances the efficacy of Tobramycin (HY-B0441) and Ciprofloxacin (HY-B0356) in a mouse wound infection model. Antibacterial synergist 3 can be used for the research of P. aeruginosa infections .
|
-
-
- HY-163481
-
|
|
Bacterial
|
Infection
|
|
Antibiofilm agent-6 (Compound 26c) is a quorum sensing inhibitor with strong antibiofilm effects that can inhibit the fluorescence intensity of PAO1-lasB-gfp and PAO1-pqsA-gfp in a concentration-dependent manner. Antibiofilm agent-6 can inhibit the production of pyocyanin and rhamnolipid. Antibiofilm agent-6 aids helps ciprofloxacin (HY-B0356) effectively eliminate the living bacteria in a mouse model infected with P. aeruginosa PAO1 .
|
-
-
- HY-130340
-
|
Teichomycin A3 factor 1; Antibiotic L 17054
|
Antibiotic
|
Infection
|
|
Teicoplanin A3-1 is a degradation product of teicoplanins A2-1 to 5 (Item Nos. 20187, 20188, 20189, 20192). Teicoplanins are glycopeptide antibiotics produced by A. teichomyceticus that are broadly effective against Gram-positive bacteria in vitro.
|
-
-
- HY-174326
-
|
|
Bacterial
|
Infection
|
|
Antibacterial agent 282 (Compound CP7), a seleno-Ciprofloxacin (HY-B0356) derivative, is an Antibacterial agent. Antibacterial agent 282 has significant antibacterial activity against gram-positive bacterium and gram-negative bacterium with MICs of 0.1-1.56 and 0.1-3.13 μg/mL, respectively (MBCs of 0.2-1.56 and 0.39-12.5 μg/mL). Antibacterial agent 282 potently disrupts and prevents biofilms formation of P. aeruginosa. Antibacterial agent 282 shows significant inhibitory activity towards the DNA gyrase from E. coli .
|
-
-
- HY-124200
-
|
|
Prostaglandin Receptor
|
Endocrinology
|
|
AL 8810 (Item No. 16735) is an 11β-fluoro analog of prostaglandin F2α which acts as a potent and selective antagonist at the FP receptor. AL 8810 isopropyl ester is a lipid soluble, esterified prodrug form of AL 8810 analogous to the commonly used therapeutic intraocular prostaglandin compounds such as Latanoprost (HY-B0577) and Travoprost (HY-B0584).
|
-
-
- HY-129303
-
|
|
Endogenous Metabolite
|
Metabolic Disease
|
|
AP39 (Item No. 17100) is a compound used to increase the levels of hydrogen sulfide (H2S) within mitochondria. It consists of a mitochondria-targeting motif (triphenylphosphonium) coupled to an H2S-donating moiety (dithiolethione) by an aliphatic linker. AP219 is a control compound for AP39, containing the triphenylphosphonium scaffold but lacking the H2S-releasing portion.
|
-
-
- HY-134123
-
|
LXB4 metHYl ester
|
Drug Intermediate
Leukotriene Receptor
|
Metabolic Disease
|
|
Lipoxin B4 (LXB4) methyl ester is a lipid soluble prodrug form of the transcellular metabolite LXB4. LXB4 is a positional isomer of LXA4 produced by the metabolism of 15-HETE or 15-HpETE by human leukocytes. At a concentration of 100 nM, LXB4 inhibits polymorphonuclear leukocyte (PMN) migration stimulated by leukotriene B4 (LTB4; Item No. 20110) and inhibits LTB4-induced adhesion of PMNs with an IC50 value of 0.3 nM.
|
-
-
- HY-B0356G
-
|
Bay-09867
|
Bacterial
Topoisomerase
Akt
β-catenin
|
Inflammation/Immunology
|
|
Ciprofloxacin GMP is Ciprofloxacin (HY-B0356) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Ciprofloxacin (Bay-09867) is an orally active, blood-brain barrier permeable fluoroquinolone antibacterial agent. Ciprofloxacin exerts bactericidal effects primarily by inhibiting topoisomerase II and IV. Ciprofloxacin inhibits the proliferation of human dental pulp stem cells and chondrocytes from young rats, and also activates the Akt signaling pathway and upregulates markers such as β-catenin and Nanog to maintain the morphological characteristics of stem cells. Ciprofloxacin induces significant neurotoxicity and tissue damage, including reducing serotonin and glutathione levels in the brain, inducing oxidative stress and depression-like behaviors, and causing articular cartilage damage. Ciprofloxacin can be applied to research related to infections of necrotic young permanent teeth and neurotoxicity .
|
-
-
- HY-NP0248A
-
|
|
Biochemical Assay Reagents
|
Inflammation/Immunology
|
|
Ciprofloxacin-OVA is a conjugate of Ciprofloxacin (HY-B0356) and Ovalbumin (OVA). By conjugating the antigen with protein adjuvants, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt the primary epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells .
|
-
-
- HY-181935
-
|
|
Bacterial
|
Infection
|
|
Antibiotic adjuvant 4 (Compound 13) is an Antibiotic adjuvant and efflux pump inhibitor. Antibiotic adjuvant 4 exhibits potent efflux pump inhibitory activity. Antibiotic adjuvant 4 significantly downregulates virulence-related genes of Staphylococcus aureus when used alone or in combination with antibiotics. Antibiotic adjuvant 4 enhances the efficacy of Ciprofloxacin (HY-B0356) against multiagent-resistant Staphylococcus aureus strains .
|
-
-
- HY-126258
-
|
|
Bacterial
DNA/RNA Synthesis
|
Infection
|
|
IMP-1700 is a potent DNA damage potentiator and antibacterial agent. IMP-1700 inhibits the bacterial SOS response to DNA damage. IMP-1700 potently sensitizes MRSA to Ciprofloxacin (HY-B0356) with an EC50 of 5.9 nM. IMP-1700 inhibits the growth of E. coli K-12 BW25113, S. aureus SH1000 and MRSA USA300 JE2 .
|
-
-
- HY-183711
-
|
|
Bacterial
Heme Oxygenase (HO)
|
Infection
|
|
Antibacterial agent 344 is an antibacterial agent with potent biofilm inhibition (IC50 = 0.27 μM). Antibacterial agent 344 inhibits heme oxygenase (HemO), impairs iron homeostasis, virulence factor production, and motility. Antibacterial agent 344 synergizes with Ciprofloxacin (HY-B0356) and Tobramycin (HY-B0441), enhancing their efficacy and delaying the development of resistance. Antibacterial agent 344 improves bacterial-infected Galleria mellonella survival, and reduces bacterial load in mice wounds. Antibacterial agent 344 can be used for the research of Pseudomonas aeruginosa infections .
|
-
-
- HY-N18102
-
|
|
Bacterial
|
Infection
|
|
3,4-Seco-mansumbinoic acid (Compound 2) is an Antibacterial agent. 3,4-Seco-mansumbinoic acid can be isolated from the oleo-resin of Commiphora molmol. 3,4-Seco-mansumbinoic acid exhibits in vitro anti-staphylococcal activity, with the strongest activity against the multidrug-resistant Staphylococcus aureus strain SA-1199B (MIC 4 μg/mL) 3,4-Seco-mansumbinoic acid displays weak potentiation of Ciprofloxacin (HY-B0356) and Tetracycline (HY-A0107) activity against strains of Salmonella enterica serovar Typhimurium SL1344 and L10. 3,4-Seco-mansumbinoic acid can be used for the research of multidrug-resistant bacterial infection (Staphylococcus aureus, Salmonella enterica serovar Typhimurium) .
|
-
-
- HY-P11615
-
|
|
Bacterial
|
Infection
|
|
FuK is a WK2-analog antimicrobial peptide modified with fluorinated unnatural amino acids. FuK has an LD50 of 72.34 mg/kg in mice, shows no hemolytic activity, with high stability against trypsin, chymotrypsin, and saline environments. FuK exerts bactericidal effects by enhancing the permeability of bacterial outer membranes, inducing depolarization of cytoplasmic membranes, and disrupting membrane potential balance against bacterias such as Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae, and MRSA. FuK exhibits synergistic antimicrobial activity with polymyxin B (HY-149179), vancomycin (HY-B0671), and ciprofloxacin (HY-B0356), and also inhibits Ciprofloxacin-induced bacterial drug resistance. FuK has in vivo safety, effectively reduces bacterial load and inflammatory cell infiltration in a mouse MRSA model, and promotes collagen fiber formation in skin wounds .
|
-
-
-
HY-L0096V
-
|
|
1,400,000 compounds
|
|
Vitas-M Screening Compounds Library (stock) contains about 1,400,000 chemical substances. They are synthetic small molecule organic compounds for biological screening and lead optimization. Select any number of items as a "cherry pick".
|
-
-
HY-L055
-
|
|
1,798 compounds
|
|
Medicine Food Homology (MFH) means that some food themselves are medicines and there is no absolute boundary between them. MFH theory combines the function of food and medicine together scientifically and MFH materials can be used both for food and medicine. Besides nutritional value, MFH materials also have the functions in the prevention and treatment of disease and many other healthcare effects. Food as medicines has many benefits because of their safety while taking drugs will bring inevitable side effect to people. In order to ensure the safe use of functional food, National Health Commission of People's Republic of China made specific provisions on MFH items. More than 100 kinds of widely used MFH materials have been released.
Based on MFH items released by National Health Commission, PRC, MCE carefully designs a unique collection of 1,798 Medicine Food Homology Compounds with high safety that can be used for high throughput and high content screening for drug discovery.
|
-
-
HY-L0088V
-
|
|
50,240 compounds
|
|
Life Chemicals presents a number of exclusive Pre-Plated Diversity Sets composed of 50,240 novel compounds with optimal physicochemical properties selected from Life Chemicals collection of newly synthesized items by dissimilarity search with an average Tanimoto threshold of 82%. These Diverse Screening Sets are ideal starting points for customers looking for a wide range of dissimilarity to screen against a number of targets from different classes or where little information is available on targeted protein structure.
|
| Cat. No. |
Product Name |
Type |
-
- HY-B0356G
-
|
Bay-09867
|
Fluorescent Dyes
|
|
Ciprofloxacin GMP is Ciprofloxacin (HY-B0356) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Ciprofloxacin (Bay-09867) is an orally active, blood-brain barrier permeable fluoroquinolone antibacterial agent. Ciprofloxacin exerts bactericidal effects primarily by inhibiting topoisomerase II and IV. Ciprofloxacin inhibits the proliferation of human dental pulp stem cells and chondrocytes from young rats, and also activates the Akt signaling pathway and upregulates markers such as β-catenin and Nanog to maintain the morphological characteristics of stem cells. Ciprofloxacin induces significant neurotoxicity and tissue damage, including reducing serotonin and glutathione levels in the brain, inducing oxidative stress and depression-like behaviors, and causing articular cartilage damage. Ciprofloxacin can be applied to research related to infections of necrotic young permanent teeth and neurotoxicity .
|
| Cat. No. |
Product Name |
Type |
-
- HY-NP0248
-
|
|
Biochemical Assay Reagents
|
|
Ciprofloxacin-BSA is a conjugate of Ciprofloxacin (HY-B0356) and BSA. By conjugating the antigen with protein adjuvants, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt the primary epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells .
|
-
- HY-B0356G
-
|
Bay-09867
|
Biochemical Assay Reagents
|
|
Ciprofloxacin GMP is Ciprofloxacin (HY-B0356) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Ciprofloxacin (Bay-09867) is an orally active, blood-brain barrier permeable fluoroquinolone antibacterial agent. Ciprofloxacin exerts bactericidal effects primarily by inhibiting topoisomerase II and IV. Ciprofloxacin inhibits the proliferation of human dental pulp stem cells and chondrocytes from young rats, and also activates the Akt signaling pathway and upregulates markers such as β-catenin and Nanog to maintain the morphological characteristics of stem cells. Ciprofloxacin induces significant neurotoxicity and tissue damage, including reducing serotonin and glutathione levels in the brain, inducing oxidative stress and depression-like behaviors, and causing articular cartilage damage. Ciprofloxacin can be applied to research related to infections of necrotic young permanent teeth and neurotoxicity .
|
-
- HY-NP0248A
-
|
|
Biochemical Assay Reagents
|
|
Ciprofloxacin-OVA is a conjugate of Ciprofloxacin (HY-B0356) and Ovalbumin (OVA). By conjugating the antigen with protein adjuvants, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt the primary epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells .
|
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P11615
-
|
|
Bacterial
|
Infection
|
|
FuK is a WK2-analog antimicrobial peptide modified with fluorinated unnatural amino acids. FuK has an LD50 of 72.34 mg/kg in mice, shows no hemolytic activity, with high stability against trypsin, chymotrypsin, and saline environments. FuK exerts bactericidal effects by enhancing the permeability of bacterial outer membranes, inducing depolarization of cytoplasmic membranes, and disrupting membrane potential balance against bacterias such as Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae, and MRSA. FuK exhibits synergistic antimicrobial activity with polymyxin B (HY-149179), vancomycin (HY-B0671), and ciprofloxacin (HY-B0356), and also inhibits Ciprofloxacin-induced bacterial drug resistance. FuK has in vivo safety, effectively reduces bacterial load and inflammatory cell infiltration in a mouse MRSA model, and promotes collagen fiber formation in skin wounds .
|
| Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
-
- HY-Y1718
-
-
-
- HY-N8606
-
-
-
- HY-N18102
-
|
|
Structural Classification
Commiphora myrrha (Nees) Engl.
Ketones, Aldehydes, Acids
Plants
Burseraceae
Source Classification
|
Bacterial
|
|
3,4-Seco-mansumbinoic acid (Compound 2) is an Antibacterial agent. 3,4-Seco-mansumbinoic acid can be isolated from the oleo-resin of Commiphora molmol. 3,4-Seco-mansumbinoic acid exhibits in vitro anti-staphylococcal activity, with the strongest activity against the multidrug-resistant Staphylococcus aureus strain SA-1199B (MIC 4 μg/mL) 3,4-Seco-mansumbinoic acid displays weak potentiation of Ciprofloxacin (HY-B0356) and Tetracycline (HY-A0107) activity against strains of Salmonella enterica serovar Typhimurium SL1344 and L10. 3,4-Seco-mansumbinoic acid can be used for the research of multidrug-resistant bacterial infection (Staphylococcus aureus, Salmonella enterica serovar Typhimurium) .
|
-
| Cat. No. |
Product Name |
Chemical Structure |
-
- HY-B0356S1
-
|
|
|
Ciprofloxacin-d8 is the deuterium labeled Ciprofloxacin. Ciprofloxacin (Bay-09867) is a fluoroquinolone antibiotic, exhibiting potent antibacterial activity.
|
-
-
- HY-B0356S
-
|
|
|
Ciprofloxacin-d8 (hydrochloride) is the deuterium labeled Ciprofloxacin. Ciprofloxacin (Bay-09867) hydrochloride is a fluoroquinolone antibiotic, exhibiting potent antibacterial activity.
|
-
-
- HY-B0356AS1
-
|
|
|
Ciprofloxacin- 13C3, 15N (Bay-09867- 13C3, 15N) monohydrochloride is 13C- and 15N-labeled Ciprofloxacin (monohydrochloride) (HY-B0356A) .
|
-
-
- HY-B0356AS
-
|
|
|
Ciprofloxacin-d8 (hydrochloride hydrate) is the deuterium labeled Ciprofloxacin hydrochloride monohydrate. Ciprofloxacin hydrochloride monohydrate is a fluoroquinolone antibiotic, exhibiting potent antibacterial activity.
|
-
-
- HY-B0356BS
-
|
|
|
Ciprofloxacin-d8 (hydrochloride monohydrate) is the deuterium labeled Ciprofloxacin (hydrochloride monohydrate). Ciprofloxacin hydrochloride is a fluoroquinolone antibiotic, exhibiting potent antibacterial activity.
|
-
-
- HY-B0356S2
-
|
|
|
Ciprofloxacin-d4 (Bay-09867-d4) is deuterium labeled Ciprofloxacin. Ciprofloxacin (Bay-09867) is a potent, orally active topoisomerase IV inhibitor. Ciprofloxacin induces mitochondrial DNA and nuclear DNA damage and lead to mitochondrial dysfunction, ROS production. Ciprofloxacin has anti-proliferative activity and induces apoptosis. Ciprofloxacin is a fluoroquinolone antibiotic, exhibiting potent antibacterial activity .
|
-
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-B0356G
-
|
Bay-09867
|
Bacterial
Topoisomerase
Akt
β-catenin
|
Inflammation/Immunology
|
|
Ciprofloxacin GMP is Ciprofloxacin (HY-B0356) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Ciprofloxacin (Bay-09867) is an orally active, blood-brain barrier permeable fluoroquinolone antibacterial agent. Ciprofloxacin exerts bactericidal effects primarily by inhibiting topoisomerase II and IV. Ciprofloxacin inhibits the proliferation of human dental pulp stem cells and chondrocytes from young rats, and also activates the Akt signaling pathway and upregulates markers such as β-catenin and Nanog to maintain the morphological characteristics of stem cells. Ciprofloxacin induces significant neurotoxicity and tissue damage, including reducing serotonin and glutathione levels in the brain, inducing oxidative stress and depression-like behaviors, and causing articular cartilage damage. Ciprofloxacin can be applied to research related to infections of necrotic young permanent teeth and neurotoxicity .
|
-
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent: